PPD has developed a variety of working groups, each comprised of a unique team of PPD medical and operational experts with long-term and applicable industry experiences. The working groups set PPD’s corporate strategy and best practices for their assigned responsibilities.
PPD’s pediatric working group brings together PPD's technical and strategic expertise into a single cross-functional global resource, with the capacity to meet our clients' broad range of pediatric product development needs.
The core pediatric working group team is supplemented by ad hoc participation of PPD's pediatric medical specialists. With twelve sub-specialty trained physicians PPD can provide medical science expertise in pediatric infectious disease, critical care, neonatology, hematology/oncology and psychiatry.
A wide network of pediatric specialists is also available for consultation across all pediatric indications.
PPD brings leading expertise in adaptive trial design, combined with the resources of a global CRO to guide your study effectively through execution.
To stay current with adaptive design developments and promote the potential advantages of adaptive trial design methodology, PPD has formed an adaptive trial design working group.
This working group organizes our adaptive design expertise into a single global resource that supports the implementation of adaptive design trials within PPD. This cross-functional group provides strategic consulting services, supports business development and external alliance development activities, and affirms PPD as an industry leader among full service providers for adaptive trials.
PPD is among a small number of companies with significant global experience in the development of pharmaceutical products in rare disease indications.
PPD has implemented approximately 600 trials in rare diseases, providing significant clinical development and operational expertise in the field and access to a broad network of investigators, particularly in hematology, oncology and infectious disease.
Through our operational expertise and our rare diseases working group, PPD provides rare disease capabilities across all stages of program development and execution that result in seamlessly integrated services.
The process for developing biosimilars is more challenging and complex than the process for developing generic small molecule drugs. The process is further intensified by the dynamic regulatory environment surrounding biosimilar drug development.
This creates the need for companies to maintain knowledge of current advances in biosimilar product development and the underlying regulatory environment. This expertise is consolidated in the biosimilar development working group, which provides a resource for PPD clients and internal teams.
The working group organizes PPD's biosimilar expertise into a single global resource that works in a cross-functional capacity to broadly meet clients' biosimilar development needs.
The group consolidates support of ongoing biosimilar projects, extends alliance development activities and provides strategic biosimilar consulting services.